ResearchMoz

U.S. Vaccine Market - U.S. Industry Analysis, Size, Share, Growth, And Forecast, 2012 - 2018

Transparency Market Research
Published Date » 2012-09-17
No. Of Pages » 71
   
 This report helps to identify factors, which will be the driving force behind the U.S. vaccine market and sub-markets in the next six years. The report provides extensive analysis of the US vaccine industry, current market trends, industry drivers and challenges for better understanding of the U.S.vaccine market structure. The report has segregated the U.S. vaccine industry in terms of product type. Annual estimates and forecasts are provided for the period 2012 through 2018 in terms of in USD million. 
   
  The report helps in providing a comprehensive overview for  
 
 
 Market forces that are driving and restraining the growth of the industry 
 Opportunities for the application segments  
 Up-to-date analysis of the latest trends in the industry  
 Acumen...
TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION
1.1 REPORT DESCRIPTION
1.2 METHODOLOGY

CHAPTER 2 EXECUTIVE SUMMARY

CHAPTER 3 U.S. VACCINE MARKET, 2012 - 2018
3.1 MARKET OVERVIEW
3.2 VACCINE MARKET CHARACTERISTICS
3.3 LAWS AND REGULATIONS
3.3.1 VACCINE APPROVAL PROCESS
3.4 U.S. VACCINE MARKET ESTIMATE AND FORECAST, 2012 - 2018
3.4.1 MARKET SHARE BY VACCINE TYPE
3.5 LIST OF COMPANIES SUPPLYING VACCINES IN THE U.S.
3.6 VACCINE PRICING
3.6.1 PRICES FOR VACCINES CONTAINING THIMEROSAL AS A PRESERVATIVE
3.6.2 PRICES OF VACCINES FREE OF PRESERVATIVES:
3.7 MARKET DYNAMICS
3.7.1 DRIVERS
3.7.1.1 Rise in incidences of viral infection driving the growth of vaccine market in the U.S.
3.7.1.2 Biotechnology research enabling synthesis of new vaccines to target complex human diseases driving the vaccine market
3.7.1.3 Government recommendation for adult and adolescent immunization will boost the growth of Vaccine market in U.S.
3.7.1.4 Rise in infectious diseases in animals driving the market
3.7.2 RESTRAINTS
3.7.2.1 Cost of refrigeration
3.7.2.2 Short functional shelf life of certain vaccines will have negative impact on the market growth
3.7.3 OPPORTUNITIES
3.7.3.1 Huge product pipeline of the multinational firms will act as an opportunity for future growth
3.8 IMPACT ANALYSIS OF DRIVERS
3.9 IMPACT ANALYSIS OF RESTRAINTS
3.10 PORTER’S FIVE FORCE ANALYSIS
3.10.1 BARGAINING POWER OF SUPPLIER
3.10.2 BARGAINING POWER OF BUYER
3.10.3 RIVALRY AMONG EXISTING COMPETITORS
3.10.4 THREAT OF NEW ENTRANTS
3.10.5 THREAT OF SUBSTITUTE

CHAPTER 4 U.S. VACCINE MARKET BY PRODUCT TYPE
4.1 HUMAN VACCINE
4.1.1 MARKET ANALYSIS, SIZE AND FORECAST
4.1.2 MARKET ATTRACTIVENESS ANALYSIS FOR HUMAN VACCINE MARKET
4.1.3 PEDIATRIC VACCINES
4.1.3.1 Market Analysis, Size and Forecast
4.1.3.2 Pediatric vaccine price list
4.1.3.3 Pediatric Influenza Vaccine price list
4.1.3.4 HaemophilusInfluenzae Type B
4.1.3.4.1 Hib Pricing
4.1.3.5 Hepatitis A
4.1.3.5.1 HAV Pricing
4.1.3.6 Hepatitis B
4.1.3.6.1 Hepatitis B Pricing
4.1.4 ADULT & ADOLESCENT VACCINES
4.1.4.1 Market Analysis, Size and Forecast
4.1.4.2 Adult vaccine price list
4.1.4.3 Adult Influenza Vaccine price list
4.1.5 OTHER HUMAN VACCINES
4.1.5.1 Market Analysis, Size and Forecast
4.2 ANIMAL VACCINE
4.2.1 MARKET ANALYSIS, SIZE AND FORECAST
4.2.2 MARKET ATTRACTIVENESS ANALYSIS FOR ANIMAL VACCINE
4.2.3 LIVESTOCK VACCINES
4.2.3.1 Market Analysis, Size and Forecast
4.2.3.2 Bovine Vaccines
4.2.3.2.1 Market Analysis, Size and Forecast
4.2.3.3 Porcine Vaccines
4.2.3.3.1 Market Analysis, Size and Forecast
4.2.3.4 Ovine Vaccines
4.2.3.4.1 Market Analysis, Size and Forecast
4.2.4 COMPANION ANIMAL VACCINES
4.2.4.1 Market Analysis, Size and Forecast
4.2.4.2 Feline Vaccines
4.2.4.2.1 Market Analysis, Size and Forecast
4.2.4.3 Canine Vaccines
4.2.4.3.1 Market Analysis, Size and Forecast
4.2.4.4 Equine Vaccines
4.2.4.4.1 Market Analysis, Size and Forecast
4.2.5 OTHER ANIMAL VACCINES
4.2.5.1 Market Analysis, Size and Forecast

CHAPTER 5 COMPETITIVE LANDSCAPE
5.1 MARKET SHARE ANALYSIS
5.2 COMPETITIVE ANALYSIS FOR KEY MARKET PLAYERS

CHAPTER 6 COMPANY PROFILE
6.1 SANOFI-AVENTIS
6.1.1 COMPANY OVERVIEW
6.1.2 FINANCIAL OVERVIEW
6.1.3 SWOT ANALYSIS
6.1.1 RECENT DEVELOPMENT
6.2 GLAXOSMITHKLINE
6.2.1 COMPANY OVERVIEW
6.2.2 FINANCIAL OVERVIEW:
6.2.3 SEGMENT OVERVIEW
6.2.4 SWOT ANALYSIS
6.2.5 RECENT DEVELOPMENTS
6.3 MERCK & COMPANY INCORPORATED
6.3.1 COMPANY OVERVIEW
6.3.2 FINANCIAL OVERVIEW:
6.3.1 RECENT DEVELOPMENT
6.4 PFIZER INCORPORATED
6.4.1 COMPANY OVERVIEW
6.4.2 FINANCIAL OVERVIEW
6.4.3 RECENT DEVELOPMENT
6.5 ASTRAZENECA PLC
6.5.1 COMPANY OVERVIEW
6.5.2 FINANCIAL OVERVIEW:
6.5.3 RECENT DEVELOPMENT
6.6 NOVARTIS AG
6.6.1 COMPANY OVERVIEW
6.6.2 FINANCIAL OVERVIEW:
6.6.3 SWOT ANALYSIS
6.6.1 RECENT DEVELOPMENT
6.7 BOEHRINGER
6.7.1 COMPANY OVERVIEW
6.7.2 NET SALES BY BUSINESS
6.7.3 SWOT ANALYSIS
6.7.4 RECENT DEVELOPMENT



List of Tables


TABLE 1 ACTS AND REGULATIONS PERTINENT TO VACCINE DEVELOPMENT 
TABLE 2 SELECT FDA AND ICH GUIDANCE DOCUMENTS RELEVANT TO VACCINE DEVELOPMENT 
TABLE 3 LOT-RELEASE TESTING GUIDLINES 
TABLE 1 U.S. VACCINE MARKET REVENUE, BY PRODUCT TYPE, 2012 - 2018, (USD MILLION) 
TABLE 2 GSK PRODUCT PIPELINE 
TABLE 3 U.S. HUMAN VACCINE MARKET REVENUE, BY PRODUCT TYPE 2012 - 2018 (USD MILLION) 
TABLE 4 U.S. ANIMAL VACCINE MARKET REVENUE, BY PRODUCT TYPE 2012 - 2018 (USD MILLION) 
TABLE 5 U.S. LIVESTOCK VACCINES MARKET REVENUE, BY PRODUCT TYPE 2012 - 2018 (USD MILLION) 
TABLE 6 U.S. COMPANION ANIMAL VACCINES MARKET REVENUE, BY PRODUCT TYPE 2012- 2018 (USD MILLION) 

List of Figures


FIG. 1 U.S. VACCINE MARKET REVENUE, BY PRODUCT TYPE, 2012 - 2018, (USD MILLION) 
FIG. 2 FDA REGULATORY REVIEW PROCESS 
FIG. 3 VACCINE APPROVAL PROCESS 
FIG. 4 U.S. VACCINE MARKET REVENUE, 2010 - 2018 (USD MILLION) 
FIG. 5 U.S. VACCINE MARKET SHARE, BY VACCINE TYPE 2012 ESTIMATE (%) 
FIG. 6 IMPACT ANALYSIS OF DRIVERS 
FIG. 7 PORTER’S FIVE FORCE ANALYSIS FOR U.S. VACCINE MARKET 
FIG. 8 U.S. HUMAN VACCINE MARKET REVENUE2010 - 2018(USD MILLION) 
FIG. 9 MARKET ATTRACTIVENESS ANALYSIS FOR U.S. HUMAN VACCINE MARKET 
FIG. 10 PEDIATRIC VACCINES MARKET REVENUE 2010 – 2018 (USD MILLION) 
FIG. 11 ADULT & ADOLESCENT VACCINESMARKETREVENUE 2010 - 2018(USD MILLION) 
FIG. 12 OTHER HUMAN VACCINESMARKETREVENUE2010 - 2018(USD MILLION) 
FIG. 13 U.S. ANIMAL VACCINEMARKETREVENUE2010 - 2018 (USD MILLION) 
FIG. 14 MARKET ATTRACTIVENESS FOR U.S. ANIMAL VACCINE MARKET2012 
FIG. 15 LIVESTOCK VACCINESMARKETREVENUE2010 - 2018 (USD MILLION) 
FIG. 16 BOVINE VACCINES MARKETREVENUE 2010 - 2018 (USD MILLION) 
FIG. 17 PORCINE VACCINESMARKETREVENUE2010 - 2018 (USD MILLION) 
FIG. 18 OVINE VACCINES MARKETREVENUE2010 - 2018 (USD MILLION) 
FIG. 19 COMPANION ANIMAL VACCINESMARKETREVENUE2010 - 2018 (USD MILLION), 
FIG. 20 FELINE VACCINESMARKETREVENUE2010-2018 (USD MILLION) 
FIG. 21 CANINE VACCINESMARKETREVENUE2010 - 2018 (USD MILLION) 
FIG. 22 EQUINE VACCINESMARKETREVENUE2010 - 2018 (USD MILLION) 
FIG. 23 OTHER ANIMAL VACCINESMARKETREVENUE2010 - 2018 (USD MILLION) 
FIG. 24 MARKET SHARE OF MAJOR HUMAN VACCINE PRODUCERS IN THE U.S., 2011 (%) 
FIG. 25 MARKET SHARE OF MAJOR ANIMAL VACCINE PRODUCERS IN THE U.S., 2011 (%) 
FIG. 26 GLOBAL VACCINE PLAYERS SALES GROWTH 2012-2018 
FIG. 27 SANOFI-AVENTIS, PERFORMANCE CHART (2009-2011) 
FIG. 28 SANOFI-AVENTIS, SWOT ANALYSIS 
FIG. 29 GLAXOSMITHKLINE PLC AG, PERFORMANCE CHART (2006-2010) 
FIG. 30 GLAXOSMITHKLINE PLC AG, MARKET SHARE BY SEGMENT IN 2011 
FIG. 31 GLAXOSMITHKLINE PLC AG, SWOT ANALYSIS 
FIG. 32 MERCK & CO. , PERFORMANCE CHART (2007-2011) 
FIG. 33 MERCK, SWOT ANALYSIS 
FIG. 34 MERCK & CO. , PERFORMANCE CHART (2007-2011) 
FIG. 35 ASTRAZENECA PLC, MARKET SHARE BY SEGMENT IN 2011 
FIG. 36 ASTRAZENECA PLC, SWOT ANALYSIS 
FIG. 37 NOVARTIS AG, PERFORMANCE CHART (2007-2011) 
FIG. 38 NOVARTIS AG, SWOT ANALYSIS 
FIG. 39 BOEHRINGER, SWOT ANALYSIS 

Upcoming Reports:

Epichlorohydrin Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012 - 2018
By - Transparency Market Research
Epichlorohydrin (ECH) is an organochlorine compound and an epoxide. It contains an organic compound having at least one chlorine covalent bond and cyclic ether rings. This is the compound mainly used for the production of epoxy resins which are used in coating, adhesives, and plastics. However, it is also used in manufacturing commercial pesticides. There are several other applications of epichlorohydrin as well. The epichlorohydrin market is expected to show growth in the coming future because of the increasing variety of uses in different product manufacturing processes....
Chromium Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Chromium is a lustrous steel-colored brittle but hard chemical. It exhibits high gloss, high melting point, excellent resistance to corrosion and is highly resistant to tarnishing. Chromium can combine with other metals to form a number of metal compounds. For instance, ferrochromium and chromium metal are produced by the aluminothermic or silicothermic reactions. Chromium is used in a wide range of applications including metallurgy, dye and pigment, wood preservation, tanning, refractory material, catalysts and magnets among others. Majority of chromium is converted into ferrochromium...
Energy Security Market (power plants) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Energy security is uninterrupted availability of energy sources at a reasonable price. Currently, world is dependent on energy supply to fuel the basic requirements such as security, transportation, public safety, communication and healthcare. Energy is the backbone for the growth of world’s greatest economies such as the United States and Europe. Developing economies have focused on optimum usage of their energy resources and power for the overall nation development. Due to rising threats across the countries these power plants and energy resources have become...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Bristol-Myers Squibb Posts USD 3.9 billion Revenues in 2014 Second Quarter
Jul 30, 2014  
Leading bio-pharmaceutical company Bristol-Myers Squibb has registered revenues of USD 3.9 billion in the 2014 second quarter. This marks a 4% decrease from the same period in 2013. The global revenues of the company (excluding the divested Diabetes Alliance), saw a 7% increase. In this quarter, the company’s results were underlined by steady global sales of nearly each of its...
Novartiss Simbrinza gets approval from the EU
Jul 30, 2014  
Glaucoma patients in Europe can easily obtain Novartis’ Simbrinza eye drops which are a combination of brimonidine tartrate and brinzolamide and it is without a beta-blocker. This eye drop has got the approval of the European Commission. Unlike the inefficient treatment provided by monotherapy, this eye drop aims at treating intraocular pressure or IOP in adults with ocular hypertension...
Second Treaty Between Zealand And Boehringer Ingelheim
Jul 30, 2014  
Denmark based Pharma group Zealand Pharma and Germany’s Boehringer Ingelheim have signed an accord to formulate new medicines for advanced and effective treatment of cardio-metabolic maladies. The collaboration between these two Pharma groups involves a new therapeutic peptide project from the list of preclinical programs of Zealand Pharma.  Both these companies are aiming...
Export market in New Zealand driven by innovative and high-value food products
Jul 29, 2014  
Demand for beverages and high value foods in Asia are driving the food and beverage industry in New Zealand. Also there is high demand for dairy products, seafood, meat and processed foods in the Asian economies which fuel the give an export boost to the economy of New Zealand.  Asia has a rapidly growing market for food which in turn is highly beneficial for New Zealand’s export...
Sony plans revival of PlayStation with network services
Jul 29, 2014  
After a nearly USD 10 billion loss over the last six years, Sony Corp has plans of reviving its consumer electronics hero – the PlayStation. Sony will be repositioning the video game console as a center of streamed network services such as social media, music and movies apart from games. The matter is still in its infancy stage of discussion and the plan is to generate revenue from the...